ReviewNeuroSci2026
Neurology-Related Research Using the German Disease Analyzer Database: A Narrative Review of Studies Published Between 2020 and 2025.
Review in NeuroSci, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe IQVIA Disease Analyzer (DA) database is a major outpatient electronic health record dataset in Germany. Over recent years, it has been increasingly used to study neurological diseases, comorbidities, treatment patterns, and long-term sequelae. We narratively summarized neurology-related studies using the German IQVIA Disease Analyzer (DA) database published since 2020 and to highlight methodological considerations relevant for interpreting DA-based neurological research.
methodsWe conducted a narrative review of DA-based studies published between January 2020 and December 2025. PubMed was searched using DA-related keywords and major neurological disease terms. Eligible articles included peer-reviewed cohort, case-control, or descriptive studies using DA outpatient data.
resultsThe review identified studies covering epilepsy, cerebrovascular outcomes, Parkinson's disease, dementia, multiple sclerosis, migraine, and sensory disorders. Most used retrospective cohort or nested case-control designs with regression or propensity score methods. Follow-up durations ranged from 3 to 10 years. Results consistently reflected routine care outpatient diagnostic and prescribing patterns. DISCUSSION: Strengths of DA studies include large patient populations, long follow-up, and detailed prescription information. Limitations include reliance on outpatient ICD-10 coding, lack of detailed neurological phenotyping, and potential residual confounding and bias.
conclusionsDA-based analyses generate clinically relevant routine care evidence on neurological conditions in the German outpatient setting. Proper methodological safeguards and complementary data sources are required to contextualize findings for clinical and epidemiological use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.